Lapatinib - Overview and Current Role in Metastatic Breast Cancer

Por Chan, Arlene
Publicado em 2006

Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness

Por Chan, Arlene
Publicado no Ther Adv Med Oncol (2016)

Pigment Epithelium-Derived Factor and Sex Hormone-Responsive Cancers

Por Brook, Naomi, Brook, Emily, Dass, Crispin R., Chan, Arlene, Dharmarajan, Arun
Publicado no Cancers (Basel) (2020)

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease

Por Chan Arlene, Morey Adrienne, Brown Belinda, Hastrich Diana, Willsher Peter, Ingram David
Publicado em 2012-11-01

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease

Por Chan, Arlene, Morey, Adrienne, Brown, Belinda, Hastrich, Diana, Willsher, Peter, Ingram, David
Publicado em 2012

A review of the importance of immune responses in luminal B breast cancer

Por Nelson, Delia J., Clark, Briony, Munyard, Kylie, Williams, Vincent, Groth, David, Gill, Jespal, Preston, Henry, Chan, Arlene
Publicado no Oncoimmunology (2017)

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib

Por Vogel, Charles, Chan, Arlene, Gril, Brunilde, Kim, Sung-Bae, Kurebayashi, Junichi, Liu, Li, Lu, Yen-Shen, Moon, Hanlim
Publicado em 2010

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer

Por De Boer, Richard H., Kotasek, Dusan, White, Shane, Koczwara, Bogda, Mainwaring, Paul, Chan, Arlene, Melara, Rebeca, Ye, Yining, Adewoye, Adeboye H., Sikorski, Robert, Kaufman, Peter A.
Publicado em 2012

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Por Dent, Rebecca A, Lindeman, Geoffrey J, Clemons, Mark, Wildiers, Hans, Chan, Arlene, McCarthy, Nicole J, Singer, Christian F, Lowe, Elizabeth S, Watkins, Claire L, Carmichael, James
Publicado em 2013

Decentralizing PrEP delivery: Implementation and dissemination strategies to increase PrEP uptake among MSM in Toronto, Canada

Por Charest, Maxime, Sharma, Malika, Chris, Allison, Schnubb, Alexandre, Knox, David C., Wilton, James, Shahin, Rita, Chan, Arlene, Mishra, Sharmistha, Grace, Daniel, Bayoumi, Ahmed M., Maxwell, John, Bogoch, Isaac I., Tan, Darrell H. S.
Publicado no PLoS One (2021)

Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP) through family physicians and sexual health clinic nurses: a dissemination and implementation study protocol

Por Sharma, Malika, Chris, Allison, Chan, Arlene, Knox, David C., Wilton, James, McEwen, Owen, Mishra, Sharmistha, Grace, Daniel, Rogers, Tim, Bayoumi, Ahmed M., Maxwell, John, Shahin, Rita, Bogoch, Isaac, Gilbert, Mark, Tan, Darrell H. S.
Publicado no BMC Health Serv Res (2018)

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Por Fasching, Peter A., Beck, J. Thaddeus, Chan, Arlene, De Laurentiis, Michele, Esteva, Francisco J., Jerusalem, Guy, Neven, Patrick, Pivot, Xavier, Bianchi, Giulia V., Martin, Miguel, Chandiwana, David, Lanoue, Brad, Ridolfi, Antonia, Wang, Yingbo, Rodriguez Lorenc, Karen, Nusch, Arnd
Publicado no Breast (2020)

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast...

Por Wolff, Antonio C., Lazar, Ann A., Bondarenko, Igor, Garin, August M., Brincat, Stephen, Chow, Louis, Sun, Yan, Neskovic-Konstantinovic, Zora, Guimaraes, Rodrigo C., Fumoleau, Pierre, Chan, Arlene, Hachemi, Soulef, Strahs, Andrew, Cincotta, Maria, Berkenblit, Anna, Krygowski, Mizue, Kang, Lih Lisa, Moore, Laurence, Hayes, Daniel F.
Publicado em 2013

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast C...

Por Baselga, José, Zamagni, Claudio, Gómez, Patricia, Bermejo, Begoña, Nagai, Shigenori E., Melichar, Bohuslav, Chan, Arlene, Mángel, Lászlo, Bergh, Jonas, Costa, Frederico, Gómez, Henry L., Gradishar, William J., Hudis, Clifford A., Rapoport, Bernardo L., Roché, Henri, Patricia, Maeda, Huang, Liping, Meinhardt, Gerold, Zhang, Joshua, Schwartzberg, Lee S.
Publicado no Clin Breast Cancer (2017)

Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer...

Por Au, Heather-Jane, Eiermann, Wolfgang, Robert, Nicholas J., Pieńkowski, Tadeusz, Crown, John, Martin, Miguel, Pawlicki, Marek, Chan, Arlene, Mackey, John, Glaspy, John, Pintér, Tamás, Liu, Mei-Ching, Fornander, Tommy, Sehdev, Sandeep, Ferrero, Jean-Marc, Bée, Valerie, Santana, Maria J., Miller, Dave P., Lalla, Deepa, Slamon, Dennis J.
Publicado em 2013

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negati...

Por Baselga, José, Gómez, Patricia, Greil, Richard, Braga, Sofia, Climent, Miguel A., Wardley, Andrew M., Kaufman, Bella, Stemmer, Salomon M., Pêgo, António, Chan, Arlene, Goeminne, Jean-Charles, Graas, Marie-Pascale, Kennedy, M. John, Ciruelos Gil, Eva Maria, Schneeweiss, Andreas, Zubel, Angela, Groos, Jutta, Melezínková, Helena, Awada, Ahmad
Publicado no J Clin Oncol (2013)

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant...

Por Gianni, Luca, Mansutti, Mauro, Anton, Antonio, Calvo, Lourdes, Bisagni, Giancarlo, Bermejo, Begoña, Semiglazov, Vladimir, Thill, Marc, Chacon, Jose Ignacio, Chan, Arlene, Morales, Serafin, Alvarez, Isabel, Plazaola, Arrate, Zambetti, Milvia, Redfern, Andrew D., Dittrich, Christian, Dent, Rebecca Alexandra, Magazzù, Domenico, De Fato, Raffaella, Valagussa, Pinuccia, Tusquets, Ignacio
Publicado no JAMA Oncol (2018)

An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer

Por Vacirca, Jeffrey L., Chan, Arlene, Mezei, Klára, Adoo, Clarence S., Pápai, Zsuzsanna, McGregor, Kimberly, Okera, Meena, Horváth, Zsolt, Landherr, László, Hanslik, Jerzy, Hager, Steven J., Ibrahim, Emad N., Rostom, Makharadze, Bhat, Gajanan, Choi, Mi Rim, Reddy, Guru, Tedesco, Karen L., Agajanian, Richy, Láng, István, Schwartzberg, Lee S.
Publicado no Cancer Med (2018)

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Por Slamon, Dennis, Eiermann, Wolfgang, Robert, Nicholas, Pienkowski, Tadeusz, Martin, Miguel, Press, Michael, Mackey, John, Glaspy, John, Chan, Arlene, Pawlicki, Marek, Pinter, Tamas, Valero, Vicente, Liu, Mei-Ching, Sauter, Guido, von Minckwitz, Gunter, Visco, Frances, Bee, Valerie, Buyse, Marc, Bendahmane, Belguendouz, Tabah-Fisch, Isabelle, Lindsay, Mary-Ann, Riva, Alessandro, Crown, John
Publicado em 2011

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Por Chia, Stephen K. L., Martin, Miguel, Holmes, Frankie A., Ejlertsen, Bent, Delaloge, Suzette, Moy, Beverly, Iwata, Hiroji, von Minckwitz, Gunter, Mansi, Janine, Barrios, Carlos H., Gnant, Michael, Tomašević, Zorica, Denduluri, Neelima, Šeparović, Robert, Kim, Sung-Bae, Jakobsen, Erik Hugger, Harvey, Vernon, Robert, Nicholas, Smith, John, Harker, Graydon, Zhang, Bo, Eli, Lisa D., Ye, Yining, Lalani, Alshad S., Buyse, Marc, Chan, Arlene
Publicado no Breast Cancer Res (2019)